GENITOURINARY CANCERS

First-line treatment with single-agent pembrolizumab induced a 24.8% overall response rate in patients with&nbsp;non-clear cell renal cell carcinoma, according to&nbsp;findings from cohort B of the phase II KEYNOTE-427 trial that were presented during the 2019 Genitourinary Cancers Symposium.<br /> &nbsp;

According to phase I findings from a dose-escalation cohort presented during the 2019 Genitourinary Cancers Symposium, the combination of pembrolizumab and cabozantinib demonstrated antitumor activity in patients with previously treated metastatic renal cell carcinoma and is tolerated at their approved doses for this indication.

Retrospective findings reported during the&nbsp;2019 Genitourinary Cancers Symposium showed&nbsp;patients with metastatic castration-resistant prostate cancer who received radium-223 dichloride with abiraterone acetate in a layered fashion experienced a lower rate of symptomatic skeletal events compared with those who received the treatments concurrently.

Adding&nbsp;enzalutamide (Xtandi) to androgen deprivation therapy led to&nbsp;prolonged radiographic progression-free survival compared with ADT alone in men with metastatic hormone-sensitive prostate cancer, investigators reported during the&nbsp;2019 Genitourinary Cancers Symposium.

According to data from the&nbsp;phase III ARAMIS trial presented during the&nbsp;2019 Genitourinary Cancers Symposium, darolutamide added to androgen deprivation therapy significantly improved metastasis-free survival compared with placebo plus ADT in patients with nonmetastatic castration-resistant prostate cancer.

According to&nbsp;the final analysis of the Prostate Cancer Prevention Trial,&nbsp;finasteride, an&nbsp;agent commonly used to treat lower urinary tract problems and baldness in men, was safe and effective in reducing the risk of prostate cancer.

Raoul S. Concepcion, MD, FACS, director, Comprehensive Prostate Center, discusses takeaways from the ARAMIS study of darolutamide in patients with nonmetastatic castration-resistant prostate cancer.

A supplemental biologics license application for the combination of pembrolizumab and axitinib has received a priority review designation from the FDA&nbsp;as a frontline treatment for patients with advanced renal cell carcinoma, primarily based on data from the phase III KEYNOTE-426 study.

In updated 30-month follow-up data from the&nbsp;phase III CheckMate-214 trial, nivolumab combined with low-dose ipilimumab sustained strong responses and a survival benefit as a frontline treatment for patients with intermediate- and poor-risk advanced renal cell carcinoma.

Although&nbsp;African-American men are at a higher risk for&nbsp;metastatic castration-resistant prostate cancer and have worse survival outcomes compared with Caucasian men, findings of a recent retrospective study suggested they may have a better response to several prostate cancer treatments.

Treatment with the&nbsp;novel targeted radiation therapy lutetium-177 PSMA-617 demonstrated&nbsp;strong clinical activity and the potential to improve survival in heavily pretreated men with PSMA-positive metastatic castration-resistant prostate cancer, according to phase II findings to be presented at the 2019 Genitourinary Cancers Symposium.

In topline findings from the phase III TITAN trial announced today by Janssen, apalutamide in combination with androgen deprivation therapy significantly improved&nbsp;radiographic progression-free survival and overall survival versus placebo in patients with metastatic castration-sensitive prostate cancer.